GlassScriptPhysician profile
Ivan J Elias
NPI 1255337879
$1,590.07
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $39.90 · 2021: $309 · 2022: $145 · 2023: $511 · 2024: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $704 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $703.66 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $462.87 | 2021-2024 | |
| Medtronic, INC. | $269.35 | 2021 | |
| Janssen Biotech, INC. | $186.70 | 2019-2024 | Stelara |
| Pfizer INC. | $115.90 | 2019 | |
| Janssen Scientific Affairs, LLC | $110.44 | 2019 | |
| Boston Scientific Corporation | $101.43 | 2023 | Exalt Model D |
| Gilead Sciences, INC. | $89.25 | 2023 | Epclusa |
| Celgene Corporation | $78.38 | 2021-2024 | Zeposia |
| Capsovision, INC. | $74.76 | 2024 | Capsocam Plus |
| Braintree Laboratories, INC. | $29.16 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $22.63 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.10 | 2024 | Gattex |
| Mauna Kea Technologies, INC. | $17.79 | 2019 | |
| Gi Supply, INC. | $13.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Elias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.